Thiazoles inhibit reactive oxygen and nitrogen species mediated diabetes mellitus: integrated in vitro and in silico insights

Thiazole heterocycles, characterized by their unique combination of sulfur and nitrogen atoms, have emerged as versatile scaffolds in medicinal chemistry. The presence of heteroatoms provide multiple binding sites, enabling rapid investigation of structure activity relationships (SARs), aiding the development of potent, and targeted inhibitors. Thiazoles exhibit remarkable tolerance to diverse functionalities, and can be readily modified to fine-tune lipophilicity, polarity, and metabolic stability, making thiazoles as valuable frameworks for hit-to-lead optimization, and drug development with favorable pharmacokinetic profiles. In this context, the current review (2020-2025) highlights: biologically inspired thiazoles, and approved drugs, synthetic approaches like condensation, multicomponent reactions, microwave-assisted synthesis, and cycloaddition strategies, recent advances in anti-oxidant, and antidiabetic thiazole analogues, analysis of SARs, and molecular docking insights into protein-ligand interactions. Thus, biological screenings reveal thiazole hybrids often outperform simple thiazoles, with several analogues demonstrating superior anti-oxidant and antidiabetic potential to drugs in free radical scavenging and enzymes inhibition assays. SARs analysis confirm electron-donating and electron-withdrawing groups around thiazole ring significantly influence inhibitory potential of the screened analogues. Molecular docking further supports these findings, showing strong intermolecular interactions that underpin enhanced bioactivity. To conclude, thiazole scaffolds represent a promising frontier in rational drug design, and discovery. Thus, the present review article emphasizes continued exploration through optimized synthetic methodologies, hybrid development, and comprehensive biological evaluation to unlock their full therapeutic potential.